In a positive development in the nation's fight to put an end tp the COVID-19 pandemic's spread, Pune based Serum Institute of India (SII)'s chief executive Adar Poonawalla has said that the company will give India priority for the delivery of the Covidshield vaccine developed by pharmaceutical major and AstraZeneca and the University of Oxford, Livemint.
Poonawalla also shared that he expected about 90 per cent of all the doses produced by it to be sold to the Government of India for around Rs 250 per piece (about $3). Meanwhile, the remaining ten per cent of the vaccines may be sold in the private market at a higher price of Rs 1,000.
Also, SII, the world's largest maker of vaccines has already produced more than 40 million doses of Covidshield and is aiming to build a stockpile of minimum 10 million doses by January.
Poonawalla also shared that the company is hoping for the emergency use license to roll out some doses of Covidshield by the end of December or January.
Meanwhile, it should also be noted that Prime Minister (PM) Narendra Modi is expected to hold a meeting with State leaders on today (24 November) to discuss the distribution of the vaccine.
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.